biostudies-literatureMcCoach CEUniversity of Colorado Lung Cancer SPORENCI NIH HHS2758-2770https://www.ebi.ac.uk/biostudies/studies/S-EPMC6157019biostudies-literatureUnknown24(12)<b>Purpose:</b> Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (<i>ALK)</i> gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify <i>ALK</i> fusions and actionable resistance mechanisms without an invasive biopsy.<b>Patients and Methods:</b> The Guardant360 (G360; Guardant Health) deidentified database of NSCLC cases was queried to identify 88 consecutive patients with 96 plasma-detected <i>ALK</i> fusions. G360 is a clinical cfDNA next-generation sequencing (NGS) test that detects point mutations, select copy number gains, fusions, insertions, and deletions in plasma.<b>Results:</b> Identified fusion partners included <i>EML4</i>Clinical cancer research : an official journal of the American Association for Cancer ResearchClinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.PMC6157019P50 CA058187P30 CA046934P50CA058187R01 CA193935Waqar SNShaw ATMcCoach CELe ATLevy BPurcell WTChue BMBlakely CMDavies KDLanman RBBanks KCDiaz JAisner DLRaymond VMDoebele RCLee CEfalseClinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.<b>Purpose:</b> Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (<i>ALK)</i> gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify <i>ALK</i> fusions and actionable resistance mechanisms without an invasive biopsy.<b>Patients and Methods:</b> The Guardant360 (G360; Guardant Health) deidentified database of NSCLC cases was queried to identify 88 consecutive patients with 96 plasma-detected <i>ALK</i> fusions. G360 is a clinical cfDNA next-generation sequencing (NGS) test that detects point mutations, select copy number gains, fusions, insertions, and deletions in plasma.<b>Results:</b> Identified fusion partners included <i>EML4</i>2018-01-01T00:00:00Z2018 Jun2025-04-04T11:20:49.222Z2019-03-27T00:11:25ZS-EPMC61570192959941010.1158/1078-0432.CCR-17-258810.1158/1078-0432.ccr-17-2588